title: Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.
abstract: Imatinib resistance remains the big hurdle for CML therapy. Previous study reveals that c-myc is important for bcr-abl CML cell proliferation, while its role in imatinib resistance is largely unknown. In this study, we first found that c-myc expression is upregulated in imatinib resistant K562R cells, which in turn enhances the expression of miR-144/451. Knockdown of c-myc or restoration of miR-144/451 in the K562R cells sensitizes K562R cells to imatinib therapy. Our study here reveals an regulatory pathway between myc and miR-144/451 and highlights that targeting either myc or miR-144/451 might be valuable for eliminating the imatinib resistant CML cells.
authors: Department of Hematology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China. liuli029@yahoo.cn
authors: Li
authors: L
authors: Liu
authors: Sitao
authors: S
authors: Wang
authors: Renan
authors: R
authors: Chen
authors: Yanlan
authors: Y
authors: Wu
authors: Bei
authors: B
authors: Zhang
authors: Siyong
authors: S
authors: Huang
authors: Jingyi
authors: J
authors: Zhang
authors: Fang
authors: F
authors: Xiao
authors: Meng
authors: M
authors: Wang
authors: Yingmin
authors: Y
authors: Liang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D055785:Gene Knockdown Techniques; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C554293:MIRN144 microRNA, human; C531201:MIRN451 microRNA, human; D035683:MicroRNAs; D010879:Piperazines; D016271:Proto-Oncogene Proteins c-myc; D011743:Pyrimidines; D000068877:Imatinib Mesylate